RPG Life Sciences Limited has released a revised investor presentation regarding the unaudited financial results for the quarter ended December 31, 2025. This updates their previous communication on January 27, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The presentation includes forward-looking statements based on certain assumptions, with the company clarifying that actual results may differ materially from these projections. The company operates in the Pharmaceutical segment. RPG Life Sciences, founded in 1979, is part of RPG Enterprises. It operates in domestic and international markets with branded formulations, global generics, and synthetic APIs. The company has three manufacturing facilities and a presence in over 50 markets. Domestic Formulations contributed 70% to total sales of Q3 FY26. The company focuses on building mega brands, expanding its global presence, and sustainable operations, supported by a capital expenditure infusion of approximately ₹140 crore. They aim to grow the immunosuppressant portfolio to over ₹200 crore and Naprosyn to over ₹100 crore. The company reported financial performance for Q3 FY26, with revenue from operations at ₹180 crore compared to ₹172.7 crore in Q3 FY25. EBITDA stood at ₹43.2 crore with a margin of 24.0%, while PBT (excluding exceptional items) was ₹37.5 crore with a margin of 20.9%. PAT (excluding exceptional items) was ₹27.9 crore with a margin of 15.5%. For 9M FY26, revenue from operations was ₹530.6 crore, EBITDA was ₹127.4 crore, PBT (excluding exceptional items) was ₹111.2 crore, and PAT (excluding exceptional items) was ₹82.6 crore. The company's long-term credit rating has been reaffirmed at A+ with a stable outlook, and the short-term rating at A1 by ICRA. Since FY22, ₹140 crore capex infused helped build modern plant with EU, TGA, PMDA, etc. approval.
